Stock listing
gettex:0FY Equillium, Inc. Aktie
German listing (gettex) of Equillium, Inc. · home listing NASDAQ:EQ
Follow Equillium, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:EQ
$1.06 USD -0.04 (-3.6%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:EQ
- Day range
- $1.06 – $1.17 USDNov 20, 2026
- Volume
- 567,889 sharesNov 20, 2026
- Market cap
- $87.26M USDAt the close on Nov 20, 2026 · price × 82.32M shares outstanding
- 52-week range
- $0.812 – $3.54 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $894,985 USDMedian day 345,656 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:EQ · Home | $1.06 USD | -0.04 (-3.6%) | 567,889 | $1.12 | $1.17 | $1.055 | $1.10 | Close on Nov 20, 2026 |
| LSE:0A4D | $1.10 USD | +0.02 (+1.9%) | 3,623 | $1.15 | $1.15 | $1.10 | $1.08 | Close on Nov 20, 2026 |
| Frankfurt:0FY | €1.005 EUR | +0.073 (+7.8%) | — | €0.97 | €1.005 | €0.97 | €0.932 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:EQ · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.06 | -0.04 | -3.6% | $1.12 | $1.17 | $1.055 | 567,889 | |
| $1.10 | -0.11 | -9.1% | $1.12 | $1.21 | $1.061 | 889,903 | |
| $1.21 | +0.06 | +5.2% | $1.15 | $1.24 | $1.15 | 619,495 | |
| $1.15 | -0.14 | -10.9% | $1.23 | $1.28 | $1.14 | 570,708 | |
| $1.29 | -0.03 | -2.3% | $1.36 | $1.36 | $1.27 | 468,848 | |
| $1.32 | -0.10 | -7.0% | $1.40 | $1.40 | $1.28 | 163,581 | |
| $1.42 | -0.035 | -2.4% | $1.47 | $1.50 | $1.41 | 215,135 | |
| $1.455 | -0.045 | -3.0% | $1.49 | $1.525 | $1.45 | 157,300 | |
| $1.50 | -0.01 | -0.7% | $1.52 | $1.61 | $1.49 | 213,287 | |
| $1.51 | +0.18 | +13.5% | $1.33 | $1.54 | $1.33 | 218,504 | |
| $1.33 | -0.07 | -5.0% | $1.38 | $1.42 | $1.25 | 271,675 | |
| $1.40 | -0.01 | -0.7% | $1.49 | $1.52 | $1.35 | 194,697 | |
| $1.41 | +0.03 | +2.2% | $1.38 | $1.455 | $1.36 | 199,083 | |
| $1.38 | +0.01 | +0.7% | $1.38 | $1.43 | $1.31 | 337,696 | |
| $1.37 | -0.05 | -3.5% | $1.38 | $1.42 | $1.29 | 310,513 | |
| $1.42 | 0.00 | 0.0% | $1.39 | $1.48 | $1.39 | 283,928 | |
| $1.42 | +0.06 | +4.4% | $1.40 | $1.43 | $1.36 | 227,331 | |
| $1.36 | +0.11 | +8.8% | $1.26 | $1.39 | $1.23 | 345,656 | |
| $1.25 | +0.02 | +1.6% | $1.20 | $1.25 | $1.17 | 192,853 | |
| $1.23 | -0.04 | -3.1% | $1.25 | $1.294 | $1.18 | 315,632 | |
| $1.27 | -0.15 | -10.6% | $1.40 | $1.42 | $1.23 | 315,473 | |
| $1.42 | +0.04 | +2.9% | $1.40 | $1.51 | $1.385 | 442,539 | |
| $1.38 | +0.14 | +11.3% | $1.25 | $1.43 | $1.24 | 774,543 | |
| $1.24 | +0.05 | +4.2% | $1.22 | $1.291 | $1.16 | 3,192,374 | |
| $1.19 | -0.13 | -9.8% | $1.32 | $1.35 | $1.19 | 466,800 | |
| $1.32 | +0.02 | +1.5% | $1.30 | $1.38 | $1.28 | 510,900 | |
| $1.30 | -0.02 | -1.5% | $1.32 | $1.38 | $1.30 | 263,700 | |
| $1.32 | -0.18 | -12.0% | $1.50 | $1.50 | $1.32 | 397,700 | |
| $1.50 | +0.09 | +6.4% | $1.42 | $1.51 | $1.39 | 383,500 | |
| $1.41 | -0.03 | -2.1% | $1.45 | $1.46 | $1.38 | 522,000 | |
| $1.44 | +0.05 | +3.6% | $1.41 | $1.46 | $1.34 | 645,000 | |
| $1.39 | -0.03 | -2.1% | $1.41 | $1.43 | $1.35 | 343,300 | |
| $1.42 | -0.03 | -2.1% | $1.39 | $1.47 | $1.37 | 393,500 | |
| $1.45 | +0.04 | +2.8% | $1.37 | $1.46 | $1.30 | 793,200 | |
| $1.41 | -0.13 | -8.4% | $1.55 | $1.60 | $1.38 | 933,800 | |
| $1.54 | -0.09 | -5.5% | $1.67 | $1.67 | $1.53 | 529,000 | |
| $1.63 | +0.01 | +0.6% | $1.63 | $1.66 | $1.58 | 3,104,100 | |
| $1.62 | -0.06 | -3.6% | $1.68 | $1.72 | $1.61 | 316,100 | |
| $1.68 | +0.01 | +0.6% | $1.65 | $1.72 | $1.63 | 241,700 | |
| $1.67 | -0.05 | -2.9% | $1.70 | $1.71 | $1.66 | 137,800 | |
| $1.72 | -0.03 | -1.7% | $1.72 | $1.74 | $1.65 | 280,700 | |
| $1.75 | -0.18 | -9.3% | $1.91 | $1.91 | $1.69 | 504,500 | |
| $1.93 | +0.03 | +1.6% | $1.90 | $1.95 | $1.81 | 3,071,700 | |
| $1.90 | -0.02 | -1.0% | $1.98 | $1.98 | $1.85 | 266,500 | |
| $1.92 | +0.03 | +1.6% | $1.89 | $2.00 | $1.86 | 853,500 | |
| $1.89 | +0.03 | +1.6% | $1.90 | $1.95 | $1.80 | 708,000 | |
| $1.86 | -0.19 | -9.3% | $2.05 | $2.06 | $1.85 | 769,700 | |
| $2.05 | -0.05 | -2.4% | $2.09 | $2.09 | $2.01 | 231,500 | |
| $2.10 | -0.01 | -0.5% | $2.10 | $2.15 | $2.06 | 261,500 | |
| $2.11 | -0.31 | -12.8% | $2.46 | $2.46 | $2.11 | 552,200 | |
| $2.42 | -0.14 | -5.5% | $2.54 | $2.69 | $2.41 | 397,300 | |
| $2.56 | +0.15 | +6.2% | $2.41 | $2.56 | $2.33 | 1,085,400 | |
| $2.41 | +0.20 | +9.0% | $2.20 | $2.47 | $2.17 | 597,900 | |
| $2.21 | -0.01 | -0.5% | $2.22 | $2.25 | $2.20 | 225,900 | |
| $2.22 | -0.03 | -1.3% | $2.26 | $2.31 | $2.18 | 152,600 | |
| $2.25 | +0.04 | +1.8% | $2.20 | $2.31 | $2.18 | 101,200 | |
| $2.21 | -0.06 | -2.6% | $2.25 | $2.26 | $2.19 | 161,200 | |
| $2.27 | -0.12 | -5.0% | $2.39 | $2.39 | $2.21 | 289,000 | |
| $2.39 | -0.06 | -2.4% | $2.46 | $2.46 | $2.33 | 232,800 | |
| $2.45 | +0.09 | +3.8% | $2.36 | $2.52 | $2.36 | 364,000 | |
| $2.36 | +0.18 | +8.3% | $2.18 | $2.47 | $2.15 | 698,700 | |
| $2.18 | -0.02 | -0.9% | $2.21 | $2.24 | $2.15 | 606,000 | |
| $2.20 | -0.11 | -4.8% | $2.31 | $2.31 | $2.18 | 326,600 | |
| $2.31 | +0.04 | +1.8% | $2.30 | $2.46 | $2.24 | 557,300 | |
| $2.27 | -0.06 | -2.6% | $2.27 | $2.33 | $2.21 | 242,500 |
- Ticker
- gettex:0FY
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- gettex
- Currency
- EUR
What changed lately
Latest news release · Nov 12, 2026
Equillium Reports Third Quarter 2026 Financial Results and Recent Corporate and Clinical Highlights
Latest deck · May 27, 2026
Webinar: Insights into the Aryl Hydrocarbon Receptor and miR-124 Axis (May 2026)
Conference · 46 slides
Latest news
Equillium Reports Third Quarter 2026 Financial Results and Recent Corporate and Clinical Highlights
Nov 12, 2026
Closed $1.29 (-2.3%) on Nov 13, 2026
Equillium to Participate in Upcoming Investor Conferences
Nov 5, 2026
Closed $1.51 (+13.5%) on Nov 6, 2026
Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504
Oct 26, 2026
Closed $1.25 (+1.6%) on Oct 26, 2026
Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
Oct 6, 2026
Closed $1.39 (-2.1%) on Oct 7, 2026
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
Oct 5, 2026
Closed $1.42 (-2.1%) on Oct 6, 2026
Equillium Announces Poster Presentations at the 7th International AHR Conference
Sep 29, 2026
Closed $1.63 (+0.6%) on Sep 30, 2026
Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum
Sep 16, 2026
Closed $1.86 (-9.3%) on Sep 16, 2026
Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Aug 13, 2026
Closed $2.36 (+17.4%) on Aug 14, 2026
Equillium Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
Jun 3, 2026
Closed $3.11 (+11.5%) on Jun 3, 2026
Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
May 28, 2026
Closed $2.84 (+8.0%) on May 28, 2026
Equillium, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 140 in all · newest Nov 12, 2026 · oldest 2019
- Decks
- 23 decks · latest May 27, 2026
Where Equillium, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:EQ · Home listing | NASDAQ | United States | USD |
| LS Exchange:A2N7B3 | LS Exchange | Germany | EUR |
| gettex:0FY · This page | gettex | Germany | EUR |
| BOATS:EQ | BOATS | United States | USD |
| LSE:0A4D | LSE | United Kingdom | USD |
| Lang & Schwarz:A2N7B3 | Lang & Schwarz | Germany | EUR |
| Dusseldorf:0FY | Dusseldorf | Germany | EUR |
| Frankfurt:0FY | Frankfurt | Germany | EUR |
| Munich:0FY | Munich | Germany | EUR |
| Stuttgart:0FY | Stuttgart | Germany | EUR |
| Tradegate:0FY | Tradegate | Germany | EUR |
Valuation
Price/book 1.7× against a median of 2.9×: 4th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $34.71M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.31
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Equillium, Inc. · NASDAQ:EQ | US$87.26M | US$34.71M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.31 |
| Bio Solution Co., Ltd. · KRX:086820 | US$88.92M | US$80.23M | 137× | 6.2× | n/a | 2.9× | 5.0% | 0.0× | n/a |
| Infant Bacterial Therapeutics AB Class B · OMXSTO:IBT_B | US$88.36M | US$77.74M | n/a | n/a | n/a | 17.0× | n/a | 0.0× | n/a |
| Y-Biologics Inc. · KRX:338840 | US$88.10M | US$71.36M | n/a | 30.1× | n/a | 6.8× | n/a | 0.9× | n/a |
| Cumberland Pharmaceuticals Inc. · NASDAQ:CPIX | US$87.57M | US$11.59M | 1.3× | 0.5× | n/a | 1.2× | 273.7% | 0.1× | 0.72 |
| Retension Pharmaceuticals, Inc. · NASDAQ:RTSN | US$87.57M | US$78.38M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Upstream Bio, Inc. · NASDAQ:UPB | US$87.15M | −US$119.4M | n/a | −41.6× | n/a | 0.4× | n/a | 0.0× | 1.95 |
| Senhwa Biosciences Inc · TPEX:6492 | US$86.77M | US$67.44M | n/a | 2,117× | n/a | 4.6× | n/a | 0.0× | n/a |
| Bioceltix SA · GPW:BCX | US$86.38M | US$72.43M | n/a | n/a | n/a | 5.6× | n/a | 0.0× | n/a |
| Perspective Therapeutics, Inc. · AMEX:CATX | US$86.05M | −US$114.1M | n/a | −570× | n/a | 0.3× | n/a | 0.0× | 1.47 |
| Pharmosa Biopharm Inc. · TPEX:6875 | US$86.04M | US$62.27M | n/a | 38.5× | n/a | 2.1× | −658.1% | 0.1× | n/a |
| Median of the others | US$87.36M | US$69.40M | 69.1× | 6.2× | 2.9× | 5.0% | 0.0× | 1.47 |
Forecasts
8 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.56 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.20 · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Bruce Steel | Chief Executive Officer |
| Stephen Connelly | President and Chief Scientific Officer |
| Christine Zedelmayer | Chief Operating Officer |
| Penny Tom | SVP Finance and Principal Accounting Officer |
| Snehal Naik | Chief Development Officer |
Board
| Director | Role |
|---|---|
| Daniel Bradbury | Chairman of the Board |
| Barbara Troupin | Director |
| Bruce Steel | Chief Executive Officer |
| Mark Pruzanski | Director |
| Martha Demski | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −2.3% |
| Q2 2026 | Aug 13, 2026 · After close | +17.4% |
| Q1 2026 | May 13, 2026 · After close | +12.1% |
| Q4 2025 | Mar 26, 2026 | −8.7% |
| Q3 2025 | Nov 13, 2025 · After close | +23.8% |
| Q2 2025 | Aug 14, 2025 · After close | +16.3% |
| Q1 2025 | May 14, 2025 · After close | +4.5% |
| Q4 2024 | Mar 27, 2025 | −46.5% |
| Q3 2024 | Nov 13, 2024 · After close | −12.3% |
| Q2 2024 | Aug 8, 2024 · After close | −1.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −15.0% |
| Q4 2023 | Mar 25, 2024 · After close | −15.6% |
| Q3 2023 | Nov 8, 2023 · After close | −4.7% |
| Q2 2023 | Aug 9, 2023 · After close | +3.9% |
| Q1 2023 | May 11, 2023 · After close | +2.1% |
| Q4 2022 | Mar 23, 2023 · After close | +11.5% |
| Q3 2022 | Nov 14, 2022 · After close | +5.3% |
| Q2 2022 | Aug 15, 2022 · After close | −1.2% |
| Q1 2022 | May 12, 2022 · After close | +0.9% |
| Q4 2021 | Mar 23, 2022 · After close | −0.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Webinar: Insights into the Aryl Hydrocarbon Receptor and miR-124 Axis (May 2026) | Conference | 46 slides | May 27, 2026 |
| Technical Presentation (November 2025) | Technical | 58 slides | Nov 5, 2025 |
| Investor Presentation (August 2025) | Investor deck | 43 slides | August 2025 |
| Technical Presentation (March 2025) | Technical | 17 slides | Mar 27, 2025 |
| Investor Presentation (November 2024) | Investor deck | 51 slides | November 2024 |
| Corporate Update (October 2024) | Corporate update | 23 slides | Oct 31, 2024 |
| Technical Presentation (June 2024) | Technical | 31 slides | June 2024 |
| Investor Day (October 2023) | Investor day | 53 slides | Oct 16, 2023 |
| Investor Presentation (February 2023) | Investor deck | 34 slides | February 2023 |
| Merger or Acquisition (December 2022) | Merger or acquisition | 7 slides | Dec 6, 2022 |
All 23 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (November 2022) | Technical | 23 slides | Nov 3, 2022 |
| Technical Presentation (September 2022) | Technical | 32 slides | Sep 27, 2022 |
| Merger or Acquisition (September 2022) | Merger or acquisition | 9 slides | Sep 7, 2022 |
| Merger or Acquisition (September 2022) | Merger or acquisition | 9 slides | Sep 6, 2022 |
| Merger or Acquisition (February 2022) | Merger or acquisition | 23 slides | Feb 16, 2022 |
| Investor Presentation (March 2021) | Investor deck | 40 slides | Mar 9, 2021 |
| Technical Presentation (February 2021) | Technical | 14 slides | Feb 12, 2021 |
| Investor Day (December 2020) | Investor day | 114 slides | Dec 4, 2020 |
| Fact Sheet (October 2020) | Fact sheet | 2 slides | Oct 25, 2020 |
| Investor Presentation (October 2019) | Investor deck | 36 slides | Oct 1, 2019 |
| Investor Presentation (May 2019) | Investor deck | 33 slides | May 1, 2019 |
| Investor Presentation (February 2019) | Investor deck | 37 slides | Feb 26, 2019 |
| Investor Presentation (November 2018) | Investor deck | 30 slides | Nov 13, 2018 |
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock and pre-funded warrants Update: about US$20M · US$0.57 a share Use of proceeds: Fund currently planned operations into 2029 | Oct 26, 2026 |
| Private placement of shares of common stock or pre-funded warrants Announced: US$30M–US$50M · US$0.57 a share · Leerink Partners +1 Dealers: Leerink Partners (lead), LifeSci Capital Buyers: ADAR1 Capital Management; Janus Henderson Investors; Adage Capital Partners LP; Coastlands Capital; Woodline Partners LP Use of proceeds: Further development of EQ504, working capital and general corporate purposes | Aug 11, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$14.00 a share on Oct 11, 2018.
- Price
- US$14.00 a share
- Shares offered
- 4,670,000 shares of common stock
- Offering size
- US$65.4 million
- Underwriters
- Jefferies, Leerink Partners, Stifel · In the order on the cover
- Shares delivered
- On or about Oct 16, 2018
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 3, 2018 |
| Filed publicly | Sep 17, 2018 |
| Amended twice | Newest Oct 2, 2018 |
| Shares registered with an exchange | Oct 5, 2018 |
| Declared effective by the SEC | Oct 11, 2018 |
| Final prospectus, with the price | Oct 12, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 12, 2018 |
| CERT · Exchange's certificate of listing | Oct 12, 2018 |
| EFFECT · Notice that a registration is effective | Oct 11, 2018 |
| CORRESP · Letter to the SEC | Oct 9, 2018 |
| CORRESP · Letter to the SEC | Oct 9, 2018 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 5, 2018 |
| CORRESP · Letter to the SEC | Oct 2, 2018 |
| S-1/A · Registration statement, amended | Oct 2, 2018 |
| UPLOAD · Letter from the SEC | Oct 1, 2018 |
| CORRESP · Letter to the SEC | Sep 28, 2018 |
All 20 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Sep 28, 2018 |
| UPLOAD · Letter from the SEC | Sep 27, 2018 |
| CORRESP · Letter to the SEC | Sep 24, 2018 |
| CORRESP · Letter to the SEC | Sep 17, 2018 |
| S-1 · Registration statement | Sep 17, 2018 |
| UPLOAD · Letter from the SEC | Sep 17, 2018 |
| DRSLTR · Letter to the SEC with a draft | Aug 30, 2018 |
| DRS/A · Draft registration statement, amended | Aug 30, 2018 |
| UPLOAD · Letter from the SEC | Aug 28, 2018 |
| DRS · Draft registration statement | Aug 3, 2018 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 12, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 130.0K | 41.1M | 36.1M | 15.8M | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 116.0K | 137.0K | 126.0K | 118.0K | 72.0K | 45.0K | 23.0K | 6.10K | 122 |
| Gross profit | -116.0K | 41.1M | 36.1M | 15.8M | -72.0K | -45.0K | -23.0K | -6.10K | -122 |
| Research and development | 12.8M | 37.4M | 37.0M | 37.5M | 26.4M | 19.4M | 17.6M | 4.94M | 1.33M |
| Selling, general and administrative | 10.8M | 11.9M | 13.6M | 17.2M | 11.4M | 10.2M | 9.09M | 3.67M | 378.3K |
| Operating income | -23.6M | -8.27M | -14.5M | -62.1M | -37.8M | -29.5M | -26.7M | -8.62M | -1.71M |
| Depreciation and amortization | 116.0K | 137.0K | 126.0K | 118.0K | 72.0K | 45.0K | 23.0K | 6.00K | 122 |
| EBITDA | -23.5M | -8.13M | -14.4M | -62.0M | -37.7M | -29.5M | -26.7M | -8.61M | -1.71M |
| Interest expense | 0 | 491.0K | 1.05M | 1.07M | 1.10M | 279.0K | 2.56M | 379.4K | |
| Income before tax | -22.4M | -7.71M | -12.8M | -62.4M | -39.1M | -29.8M | -25.6M | -13.3M | -2.26M |
| Income tax | 0 | 361.0K | 580.0K | 0 | 0 | 0 | -23.0K | 140.5K | -2 |
| Net income | -22.4M | -8.07M | -13.3M | -62.4M | -39.1M | -29.8M | -25.6M | -13.3M | -2.26M |
| Earnings per share, basic | -0.39 | -0.23 | -0.38 | -1.85 | -1.36 | -1.46 | -1.47 | -1.09 | -0.14 |
| Earnings per share, diluted | -0.39 | -0.23 | -0.38 | -1.85 | -1.36 | -1.46 | -1.47 | -1.09 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 30.3M | 18.1M | 23.2M | 59.1M | 50.4M | 24.0M | 13.2M | 28.5M | 7.10M |
| Short-term investments | 0 | 4.49M | 17.6M | 11.9M | 30.3M | 58.2M | 39.9M | 37.4M | 0 |
| Receivables | 108.0K | 0 | 3.73M | 2.84M | 0 | ||||
| Current assets | 31.0M | 25.0M | 49.3M | 76.7M | 83.4M | 85.2M | 55.4M | 67.1M | 7.15M |
| Property, plant and equipment | 164.0K | 262.0K | 315.0K | 391.0K | 237.0K | 239.0K | 93.0K | 64.0K | 2.08K |
| Total assets | 31.9M | 25.6M | 50.5M | 78.4M | 85.4M | 85.4M | 55.5M | 67.2M | 7.15M |
| Accounts payable | 755.0K | 2.68M | 4.71M | 3.98M | 1.23M | 2.77M | 1.87M | 1.12M | 243.7K |
| Current liabilities | 2.93M | 6.36M | 27.6M | 32.0M | 8.91M | 7.25M | 3.88M | 2.03M | 568.8K |
| Long-term debt | 3.24M | 8.75M | 8.28M | 9.68M | 200.0K | 8.06M | |||
| Total debt | 719.0K | 384.0K | 824.0K | 9.07M | 10.2M | 9.94M | 9.68M | 200.0K | 16.1M |
| Total liabilities | 3.29M | 6.54M | 28.0M | 46.5M | 18.9M | 15.6M | 13.7M | 2.23M | 9.40M |
| Shareholders' equity | 28.6M | 19.1M | 22.6M | 31.9M | 66.5M | 69.9M | 41.8M | 64.9M | -2.25M |
| Shares outstanding | 61.5M | 35.6M | 35.3M | 34.4M | 29.5M | 24.8M | 17.4M | 17.4M | 16.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -22.7M | -19.0M | -21.8M | -8.73M | -32.1M | -24.6M | -22.9M | -7.53M | -662.2K |
| Capital spending | -48.0K | -85.0K | -50.0K | -279.0K | -57.0K | -202.0K | -74.0K | -35.0K | -2.20K |
| Free cash flow | -22.8M | -19.1M | -21.8M | -9.01M | -32.1M | -24.8M | -23.0M | -7.56M | -664.4K |
| Cash from investing | 4.46M | 13.8M | -4.76M | 18.7M | 27.4M | -18.6M | -2.17M | -37.4M | -2.20K |
| Cash from financing | 30.4M | 164.0K | -9.23M | -1.22M | 31.1M | 53.9M | 9.84M | 66.4M | 7.77M |
| Dividends paid | -9.13M | -9.88M | |||||||
| Share buybacks | 160.0K | -260.0K | 0 | 1.15M | 53.9M | -156.0K | 64.5M | 100 | |
| Change in cash | 12.2M | -5.13M | -35.9M | 8.74M | 26.4M | 10.8M | -15.3M | 21.4M | 7.10M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| EFFECT · Notice that a registration is effective | Nov 20, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| S-3 · Registration statement | Nov 12, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 4, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 26, 2026 | Financing | SEC |
| 8-K · Current report | Oct 5, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jun 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 8-K · Current report | May 29, 2026 | Meeting outcome | SEC |
| 144 · Notice of proposed sale | May 27, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | May 7, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 17, 2026 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 15, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 15, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 15, 2026 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Apr 14, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 13, 2026 | Other filings | SEC |
| S-3 · Registration statement | Apr 7, 2026 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Mar 30, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Mar 26, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 25, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 25, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 25, 2026 | Results | SEC |
| CORRESP · Letter to the SEC | Mar 23, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 20, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 13, 2026 | Other filings | SEC |
| 8-K · Current report | Mar 13, 2026 | Material contract | SEC |
| 4/A · Change in ownership, amended | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 19, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 23, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 12, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 8, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 25, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| S-3 · Registration statement | Nov 13, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2025 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Oct 24, 2025 | Current report | SEC |
| 8-K · Current report | Oct 6, 2025 | Management or board change | SEC |
| 8-K · Current report | Sep 19, 2025 | Current report | SEC |
| 424B5 · Prospectus | Sep 19, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 19, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 16, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 16, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 11, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 11, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Sep 9, 2025 | Offer document | SEC |
| S-3 · Registration statement | Sep 9, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 8, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 4, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2025 | Material contract | SEC |
| 8-K · Current report | Aug 4, 2025 | Results | SEC |
| 144 · Notice of proposed sale | Jul 8, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 13, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Jun 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 8-K · Current report | May 22, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| DEFR14A | Apr 30, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 24, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 10, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 10, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 10, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Mar 28, 2025 | Meeting notice | SEC |
| 10-K · Annual report | Mar 27, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 6, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 13, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 12, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Nov 15, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 14, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 144 · Notice of proposed sale | Oct 31, 2024 | Other filings | SEC |
| 8-K · Current report | Oct 31, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 30, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 8-K · Current report | Jul 23, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 18, 2024 | Results | SEC |
| 144 · Notice of proposed sale | Jul 16, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 4, 2024 | Current report | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 8-K · Current report | May 23, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 11, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 11, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 11, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 1, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 1, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 25, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 25, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 25, 2024 | Results | SEC |
| 3 · Initial statement of ownership | Mar 8, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 8, 2024 | Management or board change | SEC |
| 8-K · Current report | Feb 23, 2024 | Results | SEC |
| 424B5 · Prospectus | Feb 23, 2024 | Offer document | SEC |
| 8-K · Current report | Feb 22, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Jan 19, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 21, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 8, 2023 | Results | SEC |
| 8-K · Current report | Oct 16, 2023 | Current report | SEC |
| 8-K · Current report | Oct 5, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Oct 5, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 9, 2023 | Results | SEC |
| 8-K · Current report | May 25, 2023 | Current report | SEC |
| 4 · Change in ownership | May 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2023 | Insider trade | SEC |
| 8-K · Current report | May 23, 2023 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2023 | Results | SEC |
This page holds 200 of 472 filings. Open Filings
Cap table
Built by 6ix from Equillium, Inc.’s releases · as of Nov 10, 2026
- Common shares
- 82,324,700
- Fully diluted
- 82,324,700
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 82,324,700 | Nov 10, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 10, 2026 | 82,324,700 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jason Keyes Other companies: BlossomHill Therapeutics, Inc. (Chief Financial Officer · Since at least Aug 6, 2026); Actuate Therapeutics, Inc. (Director · Since at least Aug 12, 2024); Sesen Bio Inc (Director · May 3, 2021 – Jun 22, 2022 · Past) | Chief Financial Officer · Dec 10, 2020 – Feb 14, 2025 · Past |
| Martha Demski Other companies: Alpha Teknova, Inc. (Board Member · Since at least Aug 31, 2023); ADMA Biologics Inc (Director · Mar 6, 2023 – Mar 6, 2023 · Past); Chimerix Inc (Director · May 17, 2022 – Apr 21, 2025 · Past) | Director · Since at least May 24, 2022 |
| Krishna R Polu Other companies: Frazier Lifesciences Acquisition Corp (Director · Dec 8, 2020 – Nov 22, 2022 · Past) | Chief Medical Officer · Oct 11, 2018 – Apr 22, 2020 · Past |
| Mark Pruzanski Other companies: Intercept Pharmaceuticals Inc (Director · Apr 9, 2013 – Nov 8, 2023 · Past) | Director · Since at least Oct 11, 2018 |
| Barbara Troupin | Director · Since at least Feb 24, 2022 |
| Bruce Steel | Chief Executive Officer · Since at least Oct 26, 2026 |
| Christine Zedelmayer | Chief Operating Officer · Since at least May 27, 2026 |
| Daniel Bradbury | Chairman of the Board · Since at least Nov 5, 2026 |
| Penny Tom | SVP Finance and Principal Accounting Officer · Since at least Mar 6, 2024 |
| Snehal Naik | Chief Development Officer · Since at least May 13, 2026 |
All 11 people
| Person | Seat |
|---|---|
| Stephen Connelly | President and Chief Scientific Officer · Since at least Jun 5, 2026 |
Log in to ask 6ix AI your own questions about Equillium, Inc.